Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 399

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and screening

Open access
Paluch-Shimon, S., Cardoso, F., Sessa, C., Balmana, J., Cardoso, M.J., Gilbert, F., Senkus, E.·2016·Annals of Oncology

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/annonc/mdw327

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Research works printed but not linked: 44

  1. Paul, 2014, The breast cancer susceptibility genes (BRCA) in breast and ovarian cancers, Front Biosci (Landmark Ed), 19, 605, 10.2741/4230 · DOI · Paper page
  2. King, 2003, Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2, Science, 302, 643, 10.1126/science.1088759 · DOI · Paper page
  3. Walsh, 2011, Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing, Proc Natl Acad Sci USA, 108, 18032, 10.1073/pnas.1115052108 · DOI · Paper page
  4. Mersch, 2015, Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian, Cancer, 121, 2474, 10.1002/cncr.29041 · DOI · Paper page
  5. Ford, 1998, Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium, Am J Hum Genet, 62, 676, 10.1086/301749 · DOI · Paper page
  6. Roa, 1996, Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2, Nat Genet, 14, 185, 10.1038/ng1096-185 · DOI · Paper page
  7. Gabai-Kapara, 2014, Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2, Proc Natl Acad Sci USA, 111, 14205, 10.1073/pnas.1415979111 · DOI · Paper page
  8. Evans, 2010, Risk of breast cancer in male BRCA2 carriers, J Med Genet, 47, 710, 10.1136/jmg.2009.075176 · doi:10.1136/jmg.2009.075176
  9. Tai, 2007, Breast cancer risk among male BRCA1 and BRCA2 mutation carriers, J Natl Cancer Inst, 99, 1811, 10.1093/jnci/djm203 · DOI · Paper page
  10. Warner, 2004, Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination, JAMA, 292, 1317, 10.1001/jama.292.11.1317 · DOI · Paper page
  11. Kriege, 2004, Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition, N Engl J Med, 351, 427, 10.1056/NEJMoa031759 · DOI · Paper page
  12. Kuhl, 2005, Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer, J Clin Oncol, 23, 8469, 10.1200/JCO.2004.00.4960 · DOI · Paper page
  13. Chiarelli, 2014, Effectiveness of screening with annual magnetic resonance imaging and mammography: results of the initial screen from the Ontario high risk breast screening program, J Clin Oncol, 32, 2224, 10.1200/JCO.2013.52.8331 · DOI
  14. Pijpe, 2012, Exposure to diagnostic radiation and risk of breast cancer among carriers of BRCA1/2 mutations: retrospective cohort study (GENE-RAD-RISK), BMJ, 345, e5660, 10.1136/bmj.e5660 · DOI · Paper page
  15. Phillips, 2013, Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers, J Clin Oncol, 31, 3091, 10.1200/JCO.2012.47.8313 · DOI · Paper page
  16. Narod, 2000, Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group, Lancet, 356, 1876, 10.1016/S0140-6736(00)03258-X · DOI · Paper page
  17. Hartmann, 1999, Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer, N Engl J Med, 340, 77, 10.1056/NEJM199901143400201 · DOI · Paper page
  18. Domchek, 2010, Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality, JAMA, 304, 967, 10.1001/jama.2010.1237 · DOI · Paper page
  19. Evans, 2009, Risk reducing mastectomy: outcomes in 10 European centres, J Med Genet, 46, 254, 10.1136/jmg.2008.062232 · DOI
  20. Skytte, 2011, Breast cancer after bilateral risk-reducing mastectomy, Clin Genet, 79, 431, 10.1111/j.1399-0004.2010.01604.x · DOI
  21. Mulligan, 2011, Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2, Breast Cancer Res, 13, R110, 10.1186/bcr3052 · DOI
  22. Morrow, 2009, Prophylactic mastectomy and the timing of breast reconstruction, Br J Surg, 96, 1, 10.1002/bjs.6463 · doi:10.1002/bjs.6463
  23. Niemeyer, 2011, Extended indications for nipple-sparing mastectomy, Breast J, 17, 296, 10.1111/j.1524-4741.2011.01079.x · doi:10.1111/j.1524-4741.2011.01079.x
  24. Chung, 2008, Nipple-sparing mastectomy: where are we now?, Surg Oncol, 17, 261, 10.1016/j.suronc.2008.03.004 · doi:10.1016/j.suronc.2008.03.004
  25. Kiely, 2010, Contralateral risk-reducing mastectomy in BRCA1 and BRCA2 mutation carriers and other high-risk women in the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab), Breast Cancer Res Treat, 120, 715, 10.1007/s10549-009-0497-8 · DOI
  26. Metcalfe, 2014, Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis, BMJ, 348, g226, 10.1136/bmj.g226 · DOI · Paper page
  27. Heemskerk-Gerritsen, 2015, Improved overall survival after contralateral risk-reducing mastectomy in BRCA1/2 mutation carriers with a history of unilateral breast cancer: a prospective analysis, Int J Cancer, 136, 668, 10.1002/ijc.29032 · DOI · Paper page
  28. Rebbeck, 1999, Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers, J Natl Cancer Inst, 91, 1475, 10.1093/jnci/91.17.1475 · DOI · Paper page
  29. Rebbeck, 2009, Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers, J Natl Cancer Inst, 101, 80, 10.1093/jnci/djn442 · DOI · Paper page
  30. Heemskerk-Gerritsen, 2015, Breast cancer risk after salpingo-oophorectomy in healthy BRCA1/2 mutation carriers: revisiting the evidence for risk reduction, J Natl Cancer Inst, 107, djv033, 10.1093/jnci/djv033 · DOI · Paper page
  31. Friebel, 2014, Modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: systematic review and meta-analysis, J Natl Cancer Inst, 106, dju091, 10.1093/jnci/dju091 · DOI · Paper page
  32. Menon, 2015, Risk algorithm using serial biomarker measurements doubles the number of screen-detected cancers compared with a single-threshold rule in the United Kingdom Collaborative Trial of Ovarian Cancer Screening, J Clin Oncol, 33, 2062, 10.1200/JCO.2014.59.4945 · DOI · Paper page
  33. Greene, 2008, A prospective study of risk-reducing salpingo-oophorectomy and longitudinal CA-125 screening among women at increased genetic risk of ovarian cancer: design and baseline characteristics: a Gynecologic Oncology Group study, Cancer Epidemiol Biomarkers Prev, 17, 594, 10.1158/1055-9965.EPI-07-2703 · DOI
  34. Finch, 2014, Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation, J Clin Oncol, 32, 1547, 10.1200/JCO.2013.53.2820 · DOI · Paper page
  35. Marchetti, 2014, Risk-reducing salpingo-oophorectomy: a meta-analysis on impact on ovarian cancer risk and all cause mortality in BRCA 1 and BRCA 2 mutation carriers, BMC Womens Health, 14, 150, 10.1186/s12905-014-0150-5 · DOI · Paper page
  36. Swanson, 2016, Options in prophylactic surgery to prevent ovarian cancer in high-risk women: how new hypotheses of fallopian tube origin influence recommendations, Curr Treat Options Oncol, 17, 20, 10.1007/s11864-016-0396-2 · DOI
  37. Shapira, 2015, BRCA mutation carriers show normal ovarian response in in vitro fertilization cycles, Fert Steril, 104, 1162, 10.1016/j.fertnstert.2015.07.1162 · doi:10.1016/j.fertnstert.2015.07.1162
  38. Peccatori, 2013, Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, 24, vi160, 10.1093/annonc/mdt199 · DOI · Paper page
  39. Rebbeck, 2005, Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group, J Clin Oncol, 23, 7804, 10.1200/JCO.2004.00.8151 · DOI · Paper page
  40. Santen, 2015, Vaginal administration of estradiol: effects of dose, preparation and timing on plasma estradiol levels, Climacteric, 18, 121, 10.3109/13697137.2014.947254 · DOI · Paper page
  41. Coleman, 2014, Bone health in cancer patients: ESMO Clinical Practice Guidelines, Ann Oncol, 25, iii124, 10.1093/annonc/mdu103 · DOI · Paper page
  42. Easton, 2015, Gene-panel sequencing and the prediction of breast-cancer risk, N Engl J Med, 372, 2243, 10.1056/NEJMsr1501341 · DOI · Paper page
  43. Rebbeck, 2015, Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer, JAMA, 313, 1347, 10.1001/jama.2014.5985 · DOI · Paper page
  44. Dykewicz, 2001, Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients, Clin Infect Dis, 33, 139, 10.1086/321805 · DOI · Paper page

Cited by

See all 399

Metadata

Authors
Paluch-Shimon, S., Cardoso, F., Sessa, C., Balmana, J., Cardoso, M. J., Gilbert, F., & Senkus, E.
Venue
Annals of Oncology
Publisher
Elsevier BV
Published
2016-09
Volume
27
Issue
suppl 5
Pages
v103-v110
ISSN
0923-7534 (ISSN-L)
OpenAlex
W2527255307
Cited by
399
References
5
FWCI
23.48
Type
journal article
Language
en
Open access
bronze
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and screening. https://app.cochat.ai/papers/10.1093/annonc/mdw327
The paper
Paluch-Shimon, S., Cardoso, F., Sessa, C., Balmana, J., Cardoso, M. J., Gilbert, F., & Senkus, E. (2016). Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and screening. Annals of Oncology. https://doi.org/10.1093/annonc/mdw327

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.